Fairvalue-Calculator Fairvalue-Calculator
EN DE

Rani Therapeutics Holdings (RANI) Fair Value & Analysis

Healthcare · US · Market cap $108M

Price$0.7550
Fair Value$1.32
Upside+74.8%
Quality80/100
Evidence: Low Range $0.9900 – $1.65

Fair value as of: Jun 24, 2026

Analysis

Rani Therapeutics Holdings (RANI) currently trades at $0.7550, while our model-based Fair Value estimate is $1.32 — implying the stock looks roughly 74.8% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Rani Therapeutics Holdings (RANI) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.32 versus a price of $0.7550 — about +75% (undervalued). Model-based estimate, not financial advice.
What is the fair value of RANI?
Our 21-model fair value for Rani Therapeutics Holdings is $1.32 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.7550.
What is the quality score of RANI?
Rani Therapeutics Holdings has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.